- Exclusive supply agreement signed with UK cosmetic surgery product distributor Church Pharmacy
- Strategic direction aligned with Samyang’s pursuit of digital marketing, which is expected to generate synergy
- Aims to expand sales across Europe by 2025, starting with the UK

▲ Product packaging of Croquis, a facelift thread brand of Samyang Holdings Biopharmaceuticals Division. Samyang Holdings (CEO: Eum Tae-woong) Biopharmaceuticals Division signed an exclusive supply agreement with Church Pharmacy (United Kingdom).

Croquis, a facelift thread brand of Samyang Holdings Biopharmaceuticals Division, is accelerating expansion into global markets. The brand’s name was inspired by “croquis,” a rough sketch technique used to quickly bring out subjects’ features, conveying the meaning that facial outline is lifted quickly and naturally.

Samyang Holdings (CEO: Eum Tae-woong) Biopharmaceuticals Division announced on Nov. 17 that it had signed an exclusive supply agreement with the UK medical aesthetic (cosmetic surgery) product distributor Church Pharmacy.

Church Pharmacy, headquartered in Loughborough, United Kingdom, is playing a leading role in the European cosmetic surgery market by establishing a distribution network in the UK and EU based on cosmetics and plastic surgery-related portfolios, including botulinum toxin, filler, cosmeceutical (cosmetics + pharmaceutical). In addition, Church Pharmacy has been playing a role as an opinion leader in the cosmetics surgery field by promoting products of Church Pharmacy through demonstration to UK’s doctors and patients and sharing clinical cases, based on a close cooperative relationship it had built with key doctors (competent doctors delivering new medical products and techniques to doctors).

An official from Samyang Holdings Biopharmaceuticals Division said, “Church Pharmacy has gained high trust from customers by actively carrying out the academic marketing strategy based on its solid distribution network. We signed the agreement in the beliefs that synergy effect can be created thanks to the alignment of our strategic directions as Samyang Holdings Biopharmaceuticals Division also pursue data-oriented marketing.”

Starting with this agreement, Samyang Holdings Biopharmaceuticals Division’s plans to accelerate its expansion into European markets by 2023, establishing and strengthening the sales base of five European countries, including the UK, France, Germany, Spain and Italy, and continue to expand sales across Europe by 2025.

Meanwhile, Samyang Holdings Biopharmaceuticals Division has conducted a data-oriented marketing strategy, thereby overcoming the disadvantages as a latecomer, gaining trust in the global cosmetics surgery industry. In contrast with other established companies providing cosmetic surgery threads, which put emphasis only on the comparison between before-and after-medical procedures, Samyang Holdings Biopharmaceuticals Division is building up various data to prove the correlation between the effects of medical procedures by facial area and physical properties of thread, in pursuit of evidence-based marketing.